China Zhongji Investment completes Series A investment in Wuwei Kang, achieving another victory in the "operation + investment" strategy in the greater health industry.

On April 4, 2019, China Zhongji Investment completed Series A investment in Wuwei Kang (full name "Beijing Wuwei Kang Technology Co., Ltd."). This is another investment by China Zhongji Investment in the greater health sector, following investments in Daying Technology, Zesheng Technology, and Shijiazhuang Zhongji Rehabilitation Hospital, steadily advancing its "operation + investment" strategy in the greater health sector.

Established in November 2014, Wuwei Kang is a professional company engaged in the research and development, production, sales, and health management of technologies in the mobile internet medical field. The company boasts a leading domestic R&D team in the field of intelligent medical technology, a technology-leading high-tech enterprise integrating research and development, production, sales, and service. It provides intelligent hardware for cardiovascular monitoring, as well as early warning and management service platforms.

Currently, Wuwei Kang's flagship product is a 12-lead intelligent electrocardiogram. This portable electrocardiogram, which can issue early warnings of myocardial infarction, accurately pinpoint locations, and prevent cardiovascular accidents, is currently the only integrated, portable electrocardiogram domestically and internationally with medical-grade accuracy. This electrocardiogram has outstanding features such as single-person operation, 10-second results, and professional physician recognition, and has a promising market outlook.

Wang Chunxiao, Managing Director of China Zhongji Investment, pointed out that China Zhongji Investment's investment in Wuwei Kang is primarily due to the following reasons:

Wuwei Kang's 12-lead intelligent electrocardiogram represents a breakthrough innovation.

Electrocardiogram machines on the market are divided into 12-lead and non-12-lead. Professional medical institutions only recognize 12-lead electrocardiogram machines. However, 12-lead equipment is generally complex to operate, lacks automatic diagnosis, is unsuitable for non-professionals, is unsuitable for emergency situations, and is also unaffordable for primary-level medical institutions and ordinary families.

Wuwei Kang's electrocardiogram equipment overcomes the difficulties of accuracy without convenience and convenience without accuracy, and can automatically diagnose 197 results, while achieving a price acceptable to the general public, currently unique globally, with an international patent pending. The cost of the second-generation device will be further reduced, laying a solid foundation for entry into the C-end market and providing more possibilities for the C-end operation model.

       Wuwei Kang, after two years of development, has formed a viable development strategy, establishing a market entry strategy from the B-end, building reputation and brand awareness to penetrate the C-end, and simultaneously developing both B-end and C-end markets.

Currently, the development of the B-end market has made good progress. The second-generation device has been successfully developed and obtained relevant medical device certificates, significantly reducing costs. Compared with similar products on the market, its price offers a significant cost-performance advantage, providing the necessary conditions and multiple possibilities for sales models to enter the C-end market. It is expected to achieve profitability in 2019 and exceed 10 million yuan in net profit in 2020, demonstrating significant growth potential.

      The market space is sufficiently large.

From the B-end market perspective, targeting more than 930,000 primary-level medical institutions nationwide, the market capacity exceeds 2.54 billion yuan; from the C-end perspective, targeting 260 million cardiovascular disease patients, the potential market capacity reaches 290 billion yuan, with at least 30 billion yuan of additional market space annually, presenting a huge potential market.

Yu Haipeng, founder and general manager of Wuwei Kang, introduced that Wuwei Kang holds two invention patents, with high core product technology barriers; the B-end and C-end market capacities are huge, and it is currently at the "eve" of further market development and explosion. The funds raised in this round will be mainly used for the production of the first-generation equipment, mold making and production of the second-generation equipment, service software development and promotion, service system construction, and optimization.

China Zhongji Investment, established in August 2016, has always prioritized the greater health sector in its investment strategy.

In May 2017, it completed angel investment in Daying Technology (an internet medical imaging company), and followed up with Series A investment in 2018; in May 2018, it invested in Zesheng Technology (a cutting-edge innovative drug R&D company). On September 28, 2018, Shijiazhuang Zhongji Rehabilitation Hospital, under China Zhongji Investment, commenced trial operation.

Wen Yuanhua, President of China Zhongji Investment, pointed out that with the approaching era of China's aging population, the prospect of China's greater health market is extremely broad. Currently, the three greater health equity investment projects are distributed in the fields of medical imaging, biopharmaceuticals, and medical devices, with investment stages being angel investment, early-stage investment, and Pre-IPO investment. The investment in Wuwei Kang marks the steady advancement of China Zhongji Investment's "operation + investment" system in the greater health sector. In the future, China Zhongji Investment will continue to increase its investment in sub-sectors such as biopharmaceuticals and medical services.

He emphasized that China Zhongji Investment has a very professional team of hospital operation, rehabilitation treatment, and medical investment personnel. It hopes to use "Shijiazhuang Zhongji Rehabilitation Hospital" as a base to continuously improve the dual-drive system of "medical operation + medical investment", and also hopes to cooperate with more like-minded institutions and broader social forces to cultivate the industry, make precise investments, and achieve win-win cooperation.